Caris Life Sciences (CAI) said Thursday it has launched Caris ChromoSeq, a whole genome sequencing and whole transcriptome assay designed to support the clinical genomic evaluation of myeloid malignancies.
Caris ChromoSeq can replace the multiple tests needed to identify clinically relevant mutations, structural variants in myeloid malignancie, thus, complementing a clinician's overall clinical and pathological evaluation, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments